Precision medicine firm Caris Life Sciences (Caris) and Ontada have partnered to advance oncology research and the adoption of precision medicine.
Ontada is focused on oncology real-world evidence, clinical education and point-of-care technologies.
The strategic and multi-faceted collaboration focuses on advancing molecular research and cancer care.
The goal is to improve the healthcare delivery system and support life sciences companies in developing next-generation oncology therapies.
Caris president David Spetzler said: “Rooted in a commitment to rigorous science and cancer care, the collaboration between Caris and Ontada includes strategic pillars spanning the development and delivery of multimodal data solutions, innovative research strategies and data-driven practices to provide actionable cancer care intelligence.
“By seamlessly integrating key entities of research, biopharma and patients, we collectively aim to revolutionise cancer research, drive innovation, advance precision medicine and improve patient outcomes.”
The collaboration combines Caris’ molecular-rich, multimodal database with Ontada’s real-world oncology data.
Caris’ database includes over 6.5 million tests and 13 quadrillion data points, while Ontada provides data from over 2.4 million cancer patient records across 80+ tumour types.
The data merger focuses on improving cancer care, diagnostics, and drug development.
By combining resources, both partners aim to advance oncology treatment through joint research projects.
Ontada president Christine Davis said: “By bringing together two of the most extensive clinical and genomic data sets in community oncology, we have developed a unique resource for life sciences companies.
“Our goal with this resource is to empower them to address complex questions, potentially leading to groundbreaking research and improved cancer care.”
Caris is an artificial intelligence (AI) TechBio company. It combines comprehensive molecular profiling with advanced AI and machine learning to build a large-scale, multimodal database and support the molecular complexity of disease.
This convergence of sequencing power, big data, and AI creates a platform to drive next-generation precision medicine for early detection, diagnosis, therapy selection, and drug development.
Headquartered in Texas, the precision medicine firm has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland.
In November last year, the AI TechBio company secured the US Food and Drug Administration (FDA) approval for MI Cancer Seek as a companion diagnostic (CDx) to detect cancer patients who may benefit from targeted therapies.
